Transplantation for CML: 2010

Richard T. Maziarz

doi:10.1182/blood-2009-12-255844

Transplantation for CML: 2010

Richard T. Maziarz

Knight Cancer Institute

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CMLpatients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.

Original language	English (US)
Pages (from-to)	1860-1861
Number of pages	2
Journal	Blood
Volume	115
Issue number	10
DOIs	https://doi.org/10.1182/blood-2009-12-255844
State	Published - Mar 11 2010

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2009-12-255844

Cite this

@article{812be396481c46d89cde78b420682296,

title = "Transplantation for CML: 2010",

abstract = "In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CMLpatients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.",

author = "Maziarz, {Richard T.}",

year = "2010",

month = mar,

day = "11",

doi = "10.1182/blood-2009-12-255844",

language = "English (US)",

volume = "115",

pages = "1860--1861",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "10",

}

TY - JOUR

T1 - Transplantation for CML

T2 - 2010

AU - Maziarz, Richard T.

PY - 2010/3/11

Y1 - 2010/3/11

N2 - In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CMLpatients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.

AB - In this issue of Blood, Saussele and colleagues from the German CML study group present data obtained from an interim safety analysis of a prospective multiarm trial in which allogeneic stem cell transplantation was used up front in selected low-risk CMLpatients, up front in patients presenting with advanced disease, or as planned second-line therapy after imatinib failure.

UR - http://www.scopus.com/inward/record.url?scp=77950442553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950442553&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-12-255844

DO - 10.1182/blood-2009-12-255844

M3 - Comment/debate

C2 - 20223928

AN - SCOPUS:77950442553

SN - 0006-4971

VL - 115

SP - 1860

EP - 1861

JO - Blood

JF - Blood

IS - 10

ER -

Transplantation for CML: 2010

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this